Constellation Pharmaceuticals to Participate in Two Investor Conferences

CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in two upcoming virtual investor conferences. Jigar Raythatha, CEO, will present at:

• The Bank of America Merrill Lynch Global Health Care Conference at 9:00 AM EDT on May 12

• The RBC Capital Markets Global Healthcare Virtual Conference at 10:55 AM EDT on May 20 

Live audio webcasts of Mr. Raythatha’s presentation and archives for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replay will be available for 90 days following the live presentation.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the EZH2 inhibitors CPI-1205 and CPI-0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers as well as the BET inhibitor CPI-0610 for the treatment of myelofibrosis. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.    

Contact

Kia Khaleghpour, Ph.D.Vice President, Investor Relations and CommunicationsConstellation Pharmaceuticals+1 617-844-6859[email protected]

Ronald Aldridge Investor RelationsConstellation Pharmaceuticals+1 617-714-0539[email protected]

Lauren ArnoldMedia RelationsMacDougall Biomedical Communications+1 781-235-3060[email protected]

Source: Constellation Pharmaceuticals , Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• NOAA Publishes TMC USA’s Consolidated Application for an Exploration License and Commercial Recovery Permit for TMC USA-A in the Federal Register
• CVS Health and Aetna Help Florida City Families Prepare for the School Year at Branches' Back to School Night
• LuminoCity Dino Safari Roars Back to Long Island with a New Season of Dinosaurs, Lights, and Fall Family Fun